InvestorsHub Logo
Followers 61
Posts 3376
Boards Moderated 1
Alias Born 12/26/2012

Re: None

Sunday, 09/22/2013 4:57:21 AM

Sunday, September 22, 2013 4:57:21 AM

Post# of 130513
This comes into play also IMO From 2011- Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress.

"The joint efforts of many players, starting from the discovery of a new use of MANF at UMass Medical School for diabetes, and the synergies of two highly committed organizations, has allowed us to generate a unique opportunity to launch a commercial development program for MANF as a biomarker of cellular stress and stressed beta cells in diabetes," said Dr. Fumihiko Urano, associate professor at the University of Massachusetts Medical School, who identified MANF's role in this area.

http://markets.financialcontent.com/stocks/news/read/18673668/Generex_Biotechnology_and_Amarantus_BioSciences_Announce_Oral